{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:41:47Z","timestamp":1791214907128,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T00:00:00Z","timestamp":1419206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Department of Health of Guangxi Zhuang Autonomous Region, People's Republic of China"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2017,4]]},"abstract":"Abstract<\/jats:title>\n \n Aim<\/jats:title>\n \n To evaluate the efficacy and the safety of pregabalin (\n PGB<\/jats:styled-content>\n )\u2010morphine combination for the treatment of neuropathic cancer pain (\n NCP<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n I<\/jats:styled-content>\n n this double\u2010blind, randomized, placebo (\n PL<\/jats:styled-content>\n )\u2010controlled crossover study, 40 cancer patients with severe\n NCP<\/jats:styled-content>\n were randomized into two groups (20 per group):\n PGB\u2010PL<\/jats:styled-content>\n and\n PL\u2010PGB<\/jats:styled-content>\n . Patients in the\n PGB\u2010PL<\/jats:styled-content>\n group received\n PGB<\/jats:styled-content>\n plus oral morphine in phase\n I<\/jats:styled-content>\n , and\n PL<\/jats:styled-content>\n plus oral morphine in phase\n II<\/jats:styled-content>\n . The treatment sequence for the\n PL\u2010PGB<\/jats:styled-content>\n group was\n PL<\/jats:styled-content>\n plus oral morphine in phase\n I<\/jats:styled-content>\n , and\n PGB<\/jats:styled-content>\n plus oral morphine in phase\n II<\/jats:styled-content>\n . These 2\u2010week treatment periods were separated by a 1\u2010week washout period. The primary outcome measure was the decrements in morphine dose; secondary outcomes included quantitative assessments of sleep (rated according to the Medical Outcomes Study Sleep Scale), the Constipation Assessment Scale and adverse effects.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The mean minimal effective dose of morphine was 184.4\u2009\u00b1\u200969.9\u2009mg\/day in the period of\n PGB<\/jats:styled-content>\n treatments, which was significantly lower than that of\n PL<\/jats:styled-content>\n \u2010controls (228.7\u2009\u00b1\u200966.9\u2009mg\/day;\n P<\/jats:italic>\n \u2009<\u20090.001) and baseline (247.5\u2009\u00b1\u200980.0\u2009mg\/day;\n P<\/jats:italic>\n \u2009<\u20090.001). Compared with\n PL<\/jats:styled-content>\n ,\n PGB<\/jats:styled-content>\n resulted in a significant sleep improvement as measured by sleep disturbance, sleep quantity, and sleep problems index (\n P<\/jats:italic>\n \u2009<\u20090.001), as well as a Constipation Assessment Scale reduction (\n P<\/jats:italic>\n \u2009<\u20090.001).\n PGB<\/jats:styled-content>\n resulted in a higher frequency of dry mouth and somnolence than\n PL<\/jats:styled-content>\n (\n P<\/jats:italic>\n \u2009<\u20090.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n PGB<\/jats:styled-content>\n enhances the efficacy of oral morphine and reduces dose\u2010related adverse reactions. The\n PGB<\/jats:styled-content>\n \u2010morphine combination is an effective approach to controlling\n NCP<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ajco.12311","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T05:47:10Z","timestamp":1419227230000},"source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy"],"prefix":"10.1111","volume":"13","author":[{"given":"Zhi","family":"Dou","sequence":"first","affiliation":[{"name":"Department of Pain Management First Affiliated Hospital of Guangxi Medical University Nanning Guangxi Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongbin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pain Management First Affiliated Hospital of Guangxi Medical University Nanning Guangxi Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincai","family":"Zhong","sequence":"additional","affiliation":[{"name":"Hospice Center First Affiliated Hospital of Guangxi Medical University Nanning Guangxi Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00073-1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq449"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909108322288"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1680"},{"key":"e_1_2_8_6_1","first-page":"16","article-title":"Opioids in palliative care: the NICE guidance","volume":"108","author":"Swift A","year":"2012","journal-title":"Nurs Times"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2011.00485.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90025-9"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-009-0009-1"},{"key":"e_1_2_8_10_1","first-page":"1435","article-title":"Neuropathic cancer pain: the role of adjuvant analgesics","volume":"15","author":"Farrar JT","year":"2001","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_8_11_1","first-page":"107","article-title":"Mechanisms and management of neuropathic pain in cancer","volume":"1","author":"Paice JA","year":"2003","journal-title":"J Support Oncol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00110-X"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909112443586"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.01.001"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464240-00006"},{"key":"e_1_2_8_16_1","first-page":"1","article-title":"Randomized, placebo\u2010controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life","volume":"9","author":"Boyle J","year":"2012","journal-title":"Diabetes Care"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S1715"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990425"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488710792007310"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-010-0913-6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2004.12.001"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-011-0711-0"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.12.010"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00102-8"},{"key":"e_1_2_8_26_1","first-page":"73","volume-title":"Cross\u2010over Trials in Clinical Research","author":"Senn SS","year":"2003"},{"key":"e_1_2_8_27_1","first-page":"1148","article-title":"[Case of acute exacerbation of neuropathic cancer pain rapidly relieved by simultaneous oral intake of immediate release oxycodone and pregabalin]","volume":"61","author":"Baba M","year":"2012","journal-title":"Masui"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.08.013"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909111412539"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.12.005"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1361-z"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909111418636"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2010.08.001"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0022-3565(24)29233-8","article-title":"Pregabalin enhances nonrapid eye movement sleep","volume":"299","author":"Kubota T","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/28.2.187"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000287643.13410.5e"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12311","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T14:01:43Z","timestamp":1747231303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,22]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/ajco.12311"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12311","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,22]]}}}